It has been reported that Leukocyte cell-derived chemotaxin 2 (LECT2) is involved in immune reactions (Jung et al., 2018; Lu et al., 2020), severe liver injury (Segawa et al., 2001; Okumura et al., 2017; Slowik et al., 2019), cancer (L'Hermitte et al., 2019), nonalcoholic steatohepatitis (NASH) (Takata et al., 2021), nonalcoholic fatty liver disease (NAFLD) (Yoo et al., 2017) and so on. Here, LECT2 is linked to metabolic dysfunction-associated steatotic liver disease.